Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patients

E-ISSN： 1365-2982|30|2|nmo.13247-nmo.13247

ISSN： 1350-1925

Source： NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol.30, Iss.2, 2018-02, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1093-1100

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1093-1100

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual‐dose proton pump inhibitor: Acotiamide plus usual‐dose proton pump inhibitor versus double‐dose proton pump inhibitor

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 623-630

John Wiley & Sons Inc

Access to resources Recommend Favorite

Proton Pump Inhibitor Therapy and Osteoporosis

Current Drug Safety, Vol. 3, Iss. 3, 2008-01 ,pp. : 204-209

Bentham Science Publishers

Access to resources Recommend Favorite

Using prophylactic proton pump inhibitor

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 3, 2015-03 ,pp. : 478-484

John Wiley & Sons Inc

Access to resources Recommend Favorite